

## A New Regiospecific Synthesis of Isomeric 3(4)-Aryl-4(3)-nitro-1,2,5-oxadiazole 2-Oxides

Vladimir G. Dubonos, Igor V. Ovchinnikov, Nina N. Makhova\* and Lenor I. Khmel'nitskii


N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 117913 Moscow, Russian Federation.  
Fax: +7 095 135 5328

New general, regiospecific methods of synthesis of isomeric 3(4)-aryl-4(3)-nitro-1,2,5-oxadiazole 2-oxides are suggested based on the cyclization of nitro-substituted  $\alpha$ -nitrooximes; these methods involve the action of nitrosylating reagents on  $\beta$ -nitrostyrenes and 2-aryl-2-oximino-1,1-dinitroethanes, respectively.

A limited number of examples of the synthesis of 3(4)-aryl-4(3)-substituted nitrofuraxans (1,2,5-oxadiazole 2-oxides) **1** and **2** is known,<sup>1–5</sup> and the methods reported are not of a general nature. The 3-nitro-derivatives **2** in particular are difficult to obtain. Here we suggest new regiospecific methods for synthesis of **1** and **2**. An assumption about the possibility of furoxan ring closure in Ar- and NO<sub>2</sub>-substituted  $\alpha$ -nitrooximes forms the basis of these methods. The synthesis of arylalkyl-1,2,5-oxadiazole 2-oxides using the dehydration of arylalkyl-substituted  $\alpha$ -nitrooximes has been reported.<sup>6–9</sup> The position of the NO<sub>2</sub>-group in the starting  $\alpha$ -nitrooxime determined the regiospecificity of this cyclization reaction: the oxygen atom in the NO moiety in the product always appeared on the same side as the substituent that was adjacent to the NO<sub>2</sub>-group in the starting  $\alpha$ -nitrooxime. Stabilization of the oxime fragment (in the absence of the NO-form) and conversion of the NO<sub>2</sub>-group into the *aci*-nitro form were found to be the important conditions for the dehydration process. It seemed likely that for  $\alpha$ -nitrooxime **3** (in this case it has been synthesized) these conditions could be realized, but that the conversion of the NO<sub>2</sub>-group into the *aci*-nitro form could be hindered.


An addition reaction of N<sub>2</sub>O<sub>3</sub> to the C=C bond of  $\beta$ -nitrostyrenes **5** was used to obtain **3** and at once 3-aryl-4-nitro-1,2,5-oxadiazole 2-oxides **1** were obtained. Analogously to refs. 7–10 it might be supposed that the process occurs *via* the pseudonitrosite **6**,  $\alpha$ -nitrooxime **3** and its *aci*-nitro form according to Scheme 1.†

$\alpha$ -Nitrooximes **4** were obtained by the interaction of hydroxamic acid derivatives **7** and dinitromethane sodium salt (*cf.* ref. 11) as dipotassium salts **8** (Scheme 2). Compound **4a** had been reported previously as a monopotassium salt.<sup>11†</sup> The possibility of achieving the *aci*-nitro form of  $\alpha$ -nitrooximes **4** and its ability to cyclize to form the furoxan ring were investigated in two ways using **8e**: by adding dry HCl in diethyl ether to the reaction mixture and by treatment with concentrated H<sub>2</sub>SO<sub>4</sub> with heating. As expected from the work in ref. 12 the transformation of *aci*-nitro form obtained from **8e** into the nitro derivative **4e** appeared to be more preferable than the cyclization process leading to the formation of **2e**, which was obtained in low yields in both cases (Scheme 3).†




- a; Ar = Ph
- b; Ar = *o*-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>
- c; Ar = *m*-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>
- d; Ar = *p*-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>
- e; Ar = 3,5-(NO<sub>2</sub>)<sub>2</sub>-4-MeOC<sub>6</sub>H<sub>2</sub>
- f; Ar = *p*-BrC<sub>6</sub>H<sub>4</sub>

Scheme 1 Reagents and conditions: i, NaNO<sub>2</sub> (10–15 moles), AcOH, 20–25°C, 72 h; **1a** 50%, **1b** 21%, **1c** 26%, **1d** 22%




Scheme 2 Reagents and conditions: i, *N,N*-dimethylformamide (DMF), –10–0°C, 15 h; 20°C, 3 h; ii, AcOK, MeOH, 10°C, 82–87%



**Scheme 3** Reagents and conditions: i, HCl, diethyl ether, 20°C (**2e** 4%); ii, H<sub>2</sub>SO<sub>4</sub>, 0°C, 0.5 h, 60–70°C, 0.5 h (**2e** 14%); iii, AcOK, MeOH, 10°C (**4e**, **8e** 90 and 80%, respectively)


The cyclization of **4** to form 4-aryl-3-nitro-1,2,5-oxadiazole 2-oxides **2** was successfully carried out by the interaction of nitrosylating reagents and **8**. A mixture of **1e** and **2e** was obtained by the interaction of **8e** and N<sub>2</sub>O<sub>4</sub>, and on treatment of **8e** with NaNO<sub>2</sub> in AcOH only compound **2e** was isolated. Probably, both anionic centres are nitrosylated on treatment of **8e** with N<sub>2</sub>O<sub>4</sub>, forming the intermediate **9**. The latter is transformed into cyclic compounds **1e** and **2e** with equal probability after elimination of nitrogen oxides *via* intermediate **10**. This result indicates that the process may be free radical in character (Scheme 4).†

The regioselectivity of the cyclization of compound **8**, according to Scheme 5, allows us to propose that in this case the first step of this process is nitrosylation of the dinitromethyl anion moiety of compound **8**, and the oxygen atom of the oxime group in the intermediate **11** attacks the nitrogen atom of the nitroso group. The fact that the yields of compounds **2** increased from 50–55% to 68–80% when AcOK was added to



**Scheme 4** Reagents and conditions: i, N<sub>2</sub>O<sub>4</sub> (5 moles), CHCl<sub>3</sub>, 10°C (**1e** + **2e** 26%)

the reaction mixture before carrying out the nitrosylation procedure supports this scheme. According to pK<sub>a</sub> data for **4e** (determined by UV spectroscopy) and AcOH (pK<sub>a</sub> of the dinitromethyl fragment 2.25, of the oxime fragment 4.45 and of AcOH 7.75), the quantity of the anionic form **11** in the reaction mixture must be increased as a result of such action. The participation of the oxime moiety in the ring closure was confirmed by the synthesis of <sup>15</sup>N-labelled compound **2'f** from the corresponding **7'f**. <sup>15</sup>N and <sup>13</sup>C NMR spectroscopy showed that the label was completely transferred from the starting compound to **2'f**. All compounds **2** were easily isomerized to **1** on heating in toluene (Scheme 5).†



**Scheme 5** Reagents and conditions: i, AcOK, NaNO<sub>2</sub>, AcOH, 15–20°C, (**2a** 74%, **2b** 78%, **2c** 79%, **2d** 80%, **2e** 68%, **2f** 56%, **2'f** 50%); ii, toluene, reflux, 3 h (**1** 78–85%)

† All new compounds synthesized gave satisfactory elemental analyses and were characterized by <sup>1</sup>H NMR, <sup>13</sup>C NMR, <sup>14</sup>N NMR, <sup>15</sup>N NMR and mass spectra.

**1b**: m.p. 91–92°C; <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 7.96 (m, 3H, Ar), 8.35 (m, 1H, Ar); <sup>13</sup>C NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 109.24 (C<sup>3</sup> of furoxan ring), 158.20 (C<sup>4</sup> of furoxan ring); MS *m/z* (relative intensity %) M<sup>+</sup> absent, 176 (15), 148 (44), 134 (30), 102 (100).

**1c**: m.p. 92–93°C; <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 8.35 (m, 3H, Ar), 8.63 (m, 1H, Ar); MS *m/z* 252 (M<sup>+</sup>, 3%), 222 (50), 176 (100), 148 (60), 130 (26), 118 (4), 102 (90).

**1d**: m.p. 101–102°C; <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 7.98, 8.36 (H, Ar, <sup>3</sup>J<sub>AB</sub> 9.6 Hz); MS *m/z* M<sup>+</sup> absent, 194 (28%), 176 (3), 148 (60), 118 (70), 102 (100).

**1e**: m.p. 126–127°C; <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 4.1 (s, 3H, MeO), 8.73 (s, 2H, Ar); MS *m/z* 327 (M<sup>+</sup>, 9%), 311 (2), 297 (8), 281 (20), 267 (3), 251 (100), 223 (88).

**1f**: m.p. 56.3–57.5°C; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.72 (s).

**1'f**: m.p. 56.0–57.5°C; <sup>13</sup>C NMR [CDCl<sub>3</sub>, <sup>15</sup>N] δ 108.7 (ring C<sup>3</sup> <sup>1</sup>J 24.5), 157.7 (ring C<sup>4</sup>), 118.4 (i-C, Ar, <sup>2</sup>J 1.0), 130.3 (o-C, Ar, <sup>3</sup>J 1.5), 132.6 (m-C, Ar), 126.7 (p-C, Ar, <sup>5</sup>J 0.5); <sup>15</sup>N NMR (CDCl<sub>3</sub>) (MeNO<sub>2</sub>) δ –16.2 (N<sup>3</sup>); <sup>14</sup>N NMR (CDCl<sub>3</sub>) (MeNO<sub>2</sub>) δ –35.4 (NO<sub>2</sub>).

**2b**: m.p. 127–128°C; <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 8.0 (m, 3H, Ar), 8.45 (m, 1H, Ar); <sup>13</sup>C NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 119.58 (i-C, Ar), 146.9 (CNO<sub>2</sub>, Ar), 125.23, 133.18, 133.40, 135.24 (Ar), 127.20 (ring C<sup>3</sup>), 150.09 (ring C<sup>4</sup>); MS *m/z* 252 (M<sup>+</sup>, 13%), 222 (68), 206 (100), 160 (15), 130 (17), 106 (34).

**2c**: m.p. 117–118°C; <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 8.35 (m, 3H, Ar), 8.50 (s, 1H, Ar); MS *m/z* 252 (M<sup>+</sup>, 24%), 222 (63), 176 (90), 148 (59), 130 (36), 102 (100).

**2d**: m.p. 132–133°C; <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 7.98, 8.36 (Ar, H, <sup>3</sup>J<sub>AB</sub> 9.6 Hz); <sup>13</sup>C NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 130.91 (i-C, Ar), 123.87 (m-C, Ar), 131.33 (o-C, Ar), 149.55 (p-C, Ar), 128.17 (ring C<sup>3</sup>), 151.49 (ring C<sup>4</sup>); MS *m/z* 252 (M<sup>+</sup>, 33%), 236 (5), 222 (100), 206 (14), 176 (100), 160 (12).

**2e**: m.p. 149–150°C; <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 4.08 (s, 3H, Me), 8.70 (s, 2H, Ar); <sup>13</sup>C NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 64.75 (MeO), 120.82 (i-C, Ar), 130.99 (o-C, Ar), 144.53 (m-C, Ar), 149.36 (p-C, Ar), 127.8 (ring C<sup>3</sup>), 140.36 (ring C<sup>4</sup>); MS *m/z* 327 (M<sup>+</sup>, 16%), 311 (3), 297 (10), 281 (31), 267 (3), 251 (100), 222 (21).

**2'f**: m.p. 80.0–81.3°C; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.72 (s).

**2'f**: m.p. 80.5–81.3°C; <sup>13</sup>C NMR [CDCl<sub>3</sub>, <sup>15</sup>N] δ 126.1 (ring C<sup>3</sup>), 150.5 (ring C<sup>4</sup> <sup>1</sup>J 2.6), 122.4 (C<sup>2</sup>, Ar, <sup>2</sup>J 6.2), 130.5 (o-C, Ar, <sup>3</sup>J 2.0), 132.5 (m-C, Ar), 127.3 (p-C, Ar, <sup>5</sup>J 0.6); <sup>15</sup>N NMR (CDCl<sub>3</sub>) (MeNO<sub>2</sub>) δ –12.0 (N<sup>3</sup>); <sup>14</sup>N NMR (CDCl<sub>3</sub>) (MeNO<sub>2</sub>) δ –39.7 (NO<sub>2</sub>).

**8a-f**: IR ν/cm<sup>-1</sup> 1300–1380 (NO<sub>2</sub> s), 1500–1550 (NO<sub>2</sub> as).

## References

- N. N. Makhova, I. V. Ovchinnikov, B. N. Khasapov and L. I. Khmel'nitskii, *Izv. Akad. Nauk SSSR, Ser. Khim.*, 1982, 646 (*Bull. Acad. Sci. USSR, Div. Chem. Sci.*, 1982, 583).
- R. Calvino, A. Gasco and A. Serafino, *J. Chem. Soc., Perkin Trans.* 2, 1981, 1240.
- H. Wieland, *Liebigs Ann. Chem.*, 1903, **328**, 154.
- O. A. Rakin, V. A. Ogurtsov, T. I. Godovikova and L. I. Khmel'nitskii, *Izv. Akad. Nauk SSSR, Ser. Khim.*, 1990, 1620 (*Bull. Acad. Sci. USSR, Div. Chem. Sci.*, 1990, 1469).
- A. Kunai, T. Doi, T. Nagaoka, H. Yagi and K. Sasaki, *Bull. Soc. Chem. Jpn*, 1990, **63**, 1843.
- A. Agnelli, *Gazz. Chim. Ital.*, 1892, **22**, 325.
- H. Wieland, *Liebigs Ann. Chem.*, 1903, **329**, 225.
- H. Schechter, *Rec. Chem. Progr.*, 1964, **25**, 55.
- L. I. Khmel'nitskii, S. S. Novikov and T. I. Godovikova, *Khimiya Furoksanov. Stroenie i sintez* (Chemistry of Furoxans. Structure and Synthesis), Nauka, Moscow, 1981 (in Russian).
- H. Becker, *Einführung in die Elektronentheorie Organisch-chemischer Reaktionen*, VEB Deutscher Verlag der Wissenschaften, Berlin, 1974 (in German).
- S. A. Shevelev, V. I. Erashko and A. A. Fainzilberg, *Izv. Akad. Nauk SSSR, Ser. Khim.*, 1976, 2725 (*Bull. Acad. Sci. USSR, Div. Chem. Sci.*, 1976, 2535).
- G. I. Oleneva, A. I. Ivanov, V. A. Shlyapochnikov and S. S. Novikov, *Izv. Akad. Nauk SSSR, Ser. Khim.*, 1972, 638 (*Bull. Acad. Sci. USSR, Div. Chem. Sci.*, 1972, 601).

Received: Moscow, 27th January 1992

Cambridge, 26th March 1992; Com. 2/00549B